{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:00:21Z","timestamp":1753891221229,"version":"3.41.2"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus causing the coronavirus disease of 2019. The disease has caused millions of deaths since the first pandemic at the end of 2019. Immunocompromised individuals are more likely to develop severe infections. Numerous mutations had developed in SARS-CoV-2, resulting in strains (Alfa Beta Delta Omicron) with varying degrees of virulence disease severity. In CML (chronic myeloid leukemia) patients, there is a lot of controversy regarding the effect of the treatment on the patient outcome. Some reports suggested potential better outcomes among patients with CML, likely due to the use of TKI; other reports showed no significant effects. Additionally, it is unknown how much protection immunization provides for cancer patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards, we conducted a systematic review. Retrospective, prospective studies, reviews, case series, and case reports of chronic myeloid leukemia patients aged above 18\u2009years who had SARS-CoV-2 infection were included. English literature was screened using PubMed, SCOPUS, and Google Scholar. Search terms include chronic myeloid leukemia, chronic myelogenous leukemia, and SARS-CoV-2 and Coronavirus disease 2019 (COVID-19). We searched the reference lists of the included studies for any new articles. The search included all articles published up to April 20, 2023. The review is registered in PROSPERO (registration number CRD42022326674).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We reviewed 33 articles of available published literature up to April 2023 and collected data from a total of 682 CML patients with COVID-19. Most patients were in the chronic phase, seven were in the accelerated phase, and eight were in the blast phase. Disease severity was classified according to WHO criteria. Mortality was seen in 45 patients, and there were no reports of thrombotic events. Two hundred seventy-seven patients were in the era before vaccination; among them, eight were in the intensive care unit (ICU), and mortality was 30 (11%). There were 405 patients after the era of vaccination; among them, death was reported in 15 (4%) patients and ICU in 13 patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Limitations and conclusion<\/jats:title><jats:p>The major limitation of this review is the lack of details about the use or hold of TKIs during SARS-CoV-2 infection. Additionally, after the appearance of the different variants of the SARS-CoV-2 virus, few studies mentioned the variant of the virus, which makes it difficult to compare the outcome of the other variants of the SARS-CoV-2 virus in patients with CML. Despite the limitations of the study, CML patients with COVID-19 have no significant increase in mortality compared to other hematological malignancy. Hematological cancers are associated with an increased risk of thrombosis, which is expected to increase in patients with COVID-19. However, patient with CML has not been reported to have a significant increase in thrombosis risk. The available data indicates that COVID-19\u2019s effect on patients with chronic myeloid leukemia (CML) still needs to be better understood due to the limited data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?<\/jats:ext-link> RecordID:326674.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1280271","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T04:49:53Z","timestamp":1706071793000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["SARS-CoV-2 and chronic myeloid leukemia: a systematic review"],"prefix":"10.3389","volume":"10","author":[{"given":"Elrazi A.","family":"Ali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Al-Sadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qusai","family":"Al-maharmeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eihab A.","family":"Subahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amulya","family":"Bellamkonda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhumati","family":"Kalavar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalpana","family":"Panigrahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Awni","family":"Alshurafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e2020164","DOI":"10.23750\/abm.v92i3.10796","article-title":"Priapism in patients with chronic myeloid leukemia (CML): a systematic review","author":"Ali","year":"2021","journal-title":"Acta Bio Medica: Atenei Parmensis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/ccr3.3902","article-title":"Acute appendicitis revealing a diagnosis of chronic myelogenous leukemia","volume":"9","author":"Ahmad","year":"2021","journal-title":"Clinical Case Reports"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.survophthal.2021.07.001","article-title":"Ophthalmologic manifestations as the initial presentation of chronic myeloid leukemia: a review","volume":"67","author":"Yassin","year":"2022","journal-title":"Surv Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e2020010","DOI":"10.23750\/abm.v91i3.10214","article-title":"Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: a comparative study","volume":"91","author":"Soliman","year":"2020","journal-title":"Acta Bio Medica: Atenei Parmensis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.23750\/abm.v91i4.10540","article-title":"Prevalence, clinical manifestations, and biochemical data of hypertensive versus normotensive symptomatic patients with COVID-19: a comparative study","author":"Iqbal","year":"2020","journal-title":"Acta Bio Medica: Atenei Parmensis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e925932","DOI":"10.12659\/AJCR.925932","article-title":"A case of fulminant liver failure in a 24-year-old man with coinfection with hepatitis B virus and SARS-CoV-2","volume":"21","author":"Ali","year":"2020","journal-title":"American J Case Reports"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/ccr3.3731","article-title":"Severe SARS-CoV-2 infection presenting with acute kidney injury and diabetic ketoacidosis complicated by pancreatitis in a 53-year man with hypertension","volume":"9","author":"Ali","year":"2021","journal-title":"Clinical Case Reports"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e04568","DOI":"10.1002\/ccr3.4568","article-title":"SARS-CoV-2 and guttate psoriasis: a case report and review of literature","volume":"9","author":"Ali","year":"2021","journal-title":"Clinical Case Reports"},{"year":"2019","key":"ref10","article-title":"(COVID-19) Treatment Guidelines. National Institutes of Health"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus\u2013infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1182\/blood-2021-150026","article-title":"COVID-19 in patients with chronic myeloid leukemia: poor outcomes for patients with comorbidities, older age, advanced phase disease, and those from low-income countries: an update of the candid study","volume":"138","author":"Pagnano","year":"2021","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4274\/tjh.galenos.2021.2021.0287","article-title":"Clinical characteristics and outcomes of COVID-19 in Turkish patients with hematological malignancies","volume":"39","author":"Civriz Bozda\u011f","year":"2022","journal-title":"TurkishJ Haematol: Official J Turkish Society Haematol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1001\/jama.2020.15301","article-title":"Characteristics and outcomes of COVID-19 patients during initial peak and resurgence in the Houston metropolitan area","volume":"324","author":"Vahidy","year":"2020","journal-title":"JAMA"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"eabn4947","DOI":"10.1126\/science.abn4947","article-title":"Increased risk of SARS-CoV-2 reinfection associated with emergence of omicron in South Africa","volume":"376","author":"Pulliam","year":"2022","journal-title":"Science"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1007\/s00277-023-05413-0","article-title":"Patients with chronic myeloid leukemia and coronavirus disease 2019 in the omicron era","volume":"102","author":"Qi","year":"2023","journal-title":"Ann Hematol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e25196","DOI":"10.7759\/cureus.25196","article-title":"A case series of SARS-CoV-2 omicron variant in patients with acute leukemia","volume":"14","author":"Ali","year":"2022","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1159\/000525750","article-title":"Severe acute respiratory syndrome coronavirus 2 omicron variant in patients with Philadelphia-negative myeloproliferative neoplasm: a single center experience","volume":"100","author":"Ali","year":"2022","journal-title":"Oncology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e32041","DOI":"10.7759\/cureus.32041","article-title":"SARS-CoV-2 omicron variant in patients with chronic lymphocytic leukemia: case series","volume":"14","author":"Khamees","year":"2022","journal-title":"Cureus"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s00134-021-06388-0","article-title":"Evolving changes in mortality of 13,301 critically ill adult patients with COVID-19 over 8 months","volume":"47","author":"Kurtz","year":"2021","journal-title":"Intensive Care Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e28157","DOI":"10.1002\/jmv.28157","article-title":"Anti-SARS-CoV-2 activity of targeted kinase inhibitors: repurposing clinically available drugs for COVID-19 therapy","volume":"95","author":"Boytz","year":"2023","journal-title":"J Med Virol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1099\/jgv.0.001047","article-title":"Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors","volume":"99","author":"Sisk","year":"2018","journal-title":"J Gen Virol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"8924","DOI":"10.1128\/JVI.01429-16","article-title":"Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion","volume":"90","author":"Coleman","year":"2016","journal-title":"J Virol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1053\/j.seminoncol.2021.01.003","article-title":"Differences in mortality of cancer patients with COVID-19 in a Brazilian cancer center","volume":"48","author":"Fernandes","year":"2021","journal-title":"InSeminars in Oncology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1055\/s-2007-976165","article-title":"Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F","volume":"33","author":"Tefferi","year":"2007","journal-title":"InSeminars in thrombosis and hemostasis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1160\/TH15-04-0320","article-title":"JAK-2 V617F mutation increases heparanase procoagulant activity","volume":"115","author":"Kogan","year":"2016","journal-title":"Thromb Haemost"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3389\/fphar.2020.01007","article-title":"The risk of arterial thrombosis in patients with chronic myeloid leukemia treated with second and third generation BCR-ABL tyrosine kinase inhibitors may be explained by their impact on endothelial cells: an in-vitro study","volume":"11","author":"Haguet","year":"2020","journal-title":"Front Pharmacol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1182\/blood.V124.21.1811.1811","article-title":"Arterial thrombotic complications are uncommon in patients without cardiovascular risk factors and occur at equivalent rates in chronic myeloid leukemia (CML) patients treated with imatinib and nilotinib","volume":"124","author":"Hekmatjou","year":"2014","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1002\/cncr.24257","article-title":"Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy","volume":"115","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1182\/blood-2008-09-180604","article-title":"Tyrosine kinase inhibitor\u2013induced platelet dysfunction in patients with chronic myeloid leukemia","volume":"114","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood J American Society of Hematol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/s41375-023-01893-1","article-title":"The impact of Covid-19 in patients with chronic myeloid leukemia\u2014a nationwide population-based study","volume":"37","author":"Dahl\u00e9n","year":"2023","journal-title":"Leukemia"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e24387","DOI":"10.1002\/jcla.24387","article-title":"Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: a systematic review and meta-analysis","volume":"36","author":"Naimi","year":"2022","journal-title":"J Clin Lab Anal"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.44505","article-title":"Association of remdesivir treatment with mortality among hospitalized adults with COVID-19 in the United States","volume":"5","author":"Chokkalingam","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1280271\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T04:50:03Z","timestamp":1706071803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1280271\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":34,"alternative-id":["10.3389\/fmed.2023.1280271"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1280271","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2024,1,24]]},"article-number":"1280271"}}